题名 | Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. |
链接 | http://www.sciencedirect.com/science/article/pii/S152682091170461X |
欢迎光临 科研速递论坛 (http://expaper.cn/) | Powered by Discuz! X2.5 |